Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE

Switching from Dupilumab to Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of Efficacy After Treatment With Dupilumab in JADE DARE

Abstract Introduction Primary results of the JADE DARE trial (NCT04345367) demonstrated that abrocitinib was superior to dupilumab in reducing the signs and symptoms of moderate-to-severe atopic dermatitis (AD). This post hoc analysis evaluated the efficacy and safety of abrocitinib in patients with...

Full description

Saved in:
Bibliographic Details
Main Authors: Jonathan I. Silverberg, Eric L. Simpson, Andrew E. Pink, Stephan Weidinger, Gary Chan, Pinaki Biswas, Claire Clibborn, Erman Güler
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-02-01
Series:Dermatology and Therapy
Subjects:
Abrocitinib
Atopic dermatitis
Dupilumab
JAK-1 selective inhibitor
Nonresponders
Responders
Online Access:https://doi.org/10.1007/s13555-024-01320-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s13555-024-01320-y

Similar Items